Health Care/Hospital
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
* Over 600 Medical Professionals from 25 Countries Participate * Launch of 'IRC' Committee for Rejuran Global Research Team SEONGNAM, South Korea, Nov. 1, 2024 /PRNewswire/ -- PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch ...
2024-11-01 14:01
1659
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to comp...
2024-11-01 11:34
1554
National Comprehensive Cancer Network Joins with Vietnam National Cancer Hospital to Enhance Cancer Treatment
International collaboration meets in Vietnam to facilitate treatment recommendation guidelines that help people with cancer to live better lives. HANOI, Vietnam, Nov. 1, 2024 /PRNewswire/ -- As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National...
2024-11-01 10:04
2274
CARsgen® U.S. Clinical Holds Lifted by FDA
SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration ("FDA") lifted the clinica...
2024-11-01 09:33
1707
Zepp Health Launches Enhanced Zepp App 9: Elevating Personalized Health and Wellness for Amazfit Users Worldwide
MILPITAS, Calif., Oct. 31, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced the launch of the enhancedZepp App 9. This latest app version is designed to deliver a more personalized health, wellness...
2024-10-31 23:00
2930
Bridging Geographical Boundaries: Abrobo's Groundbreaking Contribution to China Medical Innovation-- the World's First Live Broadcast of Remote Cerebrovascular Interventional Operation on Animal at an Academic Conference
SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- This golden October, great minds gathered to embark on a new chapter of innovation. The 2024 Oriental Conference of Interventional Neurovascology (OCIN 2024), a premier event in neurovascular treatment, was held successfully fromOctober 25th to 27th at the ...
2024-10-31 22:54
8277
HKUST Spearheads Four Large AI Models to Revolutionize Healthcare
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- In a groundbreaking initiative, The Hong Kong University of Science and Technology (HKUST) has unveiled four AI-driven models poised to transform the medical and healthcare fields. These AI models can assist both general and specialist medical practitioner...
2024-10-31 21:46
2170
Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") inPortugal, for exclusive rights to the commercialization of clobetasol propionate oph...
2024-10-31 21:36
1685
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024
WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...
2024-10-31 21:00
1040
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...
2024-10-31 20:14
1425
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...
2024-10-31 20:00
1111
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...
2024-10-31 19:00
1567
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the imm...
2024-10-31 18:00
1191
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...
2024-10-31 14:31
1144
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...
2024-10-31 13:00
2084
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...
2024-10-31 12:34
1669
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...
2024-10-31 12:02
1567
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients
ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains th...
2024-10-31 12:00
1816
MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024
SHENZHEN, China, Oct. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI")
2024-10-31 10:51
1462
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration
DONGGUAN, China, Oct. 30, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership ...
2024-10-31 10:26
1392
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 294 media titles]
2025-01-14 21:00
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04LANDI Global Unveils Flagship Cx20: Elevating business efficiency and customer experience with a next-generation Windows-powered terminal
[Picked up by 274 media titles]
2025-01-11 22:30
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
21017
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
6491
Boqii Announces ADS Ratio Change
2025-01-11 05:30
5240
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
5202
